J. E. Crowe

Functional and antigenic landscape of the Nipah virus receptor binding protein

This study uses deep mutational scanning to analyze how mutations in the Nipah virus receptor-binding protein affect function, receptor binding, and antibody escape, revealing constrained regions and limited antigenic variation in natural strains.

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants

This paper computationally redesigns an antibody to restore potency against SARS-CoV-2 Omicron subvariants while maintaining efficacy against Delta and other variants.

Prototype mRNA vaccines imprint broadly neutralizing human serum antibodies after Omicron variant-matched boosting

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.

Potently neutralizing human monoclonal antibodies against the zoonotic pararubulavirus Sosuga virus

The paper identifies potent human monoclonal antibodies against Sosuga virus, revealing epitope diversity and neutralization mechanisms.

Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies

This study maps antigenic sites and characterizes neutralizing antibodies against hantaviruses, identifying mechanisms and cross-protective potential for vaccine development.

Computational epitope mapping of class I fusion proteins using Bayes classification

This paper introduces AxIEM, a Bayesian classifier for predicting epitopes on class I viral fusion proteins, showing improved accuracy over existing methods.

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

This study evaluates the effectiveness of S309 and AZD7442 monoclonal antibodies against Omicron variants in mice, showing reduced lung infection despite decreased neutralization in vitro.

Isolation of a potently neutralizing and protective human monoclonal antibody targeting yellow fever virus

The paper isolates a human monoclonal antibody that neutralizes yellow fever virus and provides therapeutic protection in animal models.

Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes

The paper analyzes the human antibody response to ebolavirus glycoprotein, identifying public clonotypes with neutralizing activity and implications for vaccine design.

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer

The paper identifies a rare antibody that targets the SARS-CoV-2 spike trimer interface, disrupting viral entry and providing protection in mice.

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies

This study evaluates the neutralization of the SARS-CoV-2 Omicron variant by therapeutic monoclonal antibodies and finds that several lose efficacy against the variant.

Neutralization Fingerprinting Technology for Characterizing Polyclonal Antibody Responses to Dengue Vaccines

This study presents a computational framework to analyze neutralizing antibody specificities in response to dengue vaccines, revealing differences in immune responses based on prior infection status.

Structural mapping of antibody landscapes to human betacoronavirus spike proteins

The paper maps epitopes of polyclonal antibodies against beta-coronavirus spike proteins in human sera, revealing cross-reactive patterns between seasonal and SARS-2 infections.

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques

This study shows that a combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques and neutralizes variants of concern in vitro.

Protective transfer: Maternal passive immunization with a rotavirus-neutralizing dimeric IgA protects against rotavirus disease in suckling neonates

Single-Cell Profiling of the Antigen-Specific Response to BNT162b2 SARS-CoV-2 RNA Vaccine

Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking

This study demonstrates that integrating ligand blocking into LIBRA-seq improves the efficiency of identifying potent SARS-CoV-2 neutralizing antibodies.

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition

This study identifies a potent SARS-CoV-2 antibody, 54042-4, that neutralizes variants of concern and has a unique epitope and genetic structure.

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.

Protective pan-ebolavirus combination therapy by two multifunctional human antibodies

This paper develops a therapeutic cocktail of two human antibodies that protect against multiple ebolaviruses in non-human primates and reveals their molecular mechanisms.

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

Functional cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein

This study identifies human monoclonal antibodies that neutralize HeV and NiV by targeting distinct antigenic sites on the receptor binding protein and demonstrates their cooperative binding and synergistic therapeutic effects.

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

This paper determines the structures of two antibodies in the AZD7442 cocktail that neutralize SARS-CoV-2 and identifies critical residues for neutralization and viral escape.

Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein

The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.

Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface

The paper identifies common genetic and structural features of human antibodies recognizing the influenza HA trimer interface, suggesting it as a target for vaccine design.

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection

This study shows that neutralizing antibodies against SARS-CoV-2 need intact Fc functions and monocytes for optimal therapeutic protection in animal models.

Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions

The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.

Convergence of a common solution to broad ebolavirus neutralization by glycan cap directed human antibodies

The paper presents cryo-EM structures of glycan cap antibodies that neutralize ebolavirus by targeting a conserved MLD-anchor site, revealing common features among broadly neutralizing antibodies.

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

This study maps mutations in the SARS-CoV-2 spike RBD that escape antibody recognition, revealing escape mutation patterns and enabling the design of antibody cocktails.

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.